COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.

New investigational drug for advanced or metastatic solid tumor cancers

Trial ID:
IRB-20-7578
Darren Sigal, M.D.
The purpose of this open label study is to test the safety and effectiveness of OBI-888 (investigational study drug), given weekly via intravenous infusion (IV), in patients with locally advanced or metastatic solid tumor cancer.

Inclusion Criteria

Patients must:
  • Be 18 yrs of age or older
  • Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light house work, or office work.
  • Have a tissue specimen from a prior biopsy or recent biopsy to be submitted for Globo H analysis

Exclusion Criteria

Patients must not:
  • Be pregnant or nursing
  • Have an active autoimmune or inflammatory disease requiring systemic treatment within the past 2Months, or autoimmune disease that requires systemic steroids or other immunosuppressive medications
  • Have a history of solid organ transplant
  • Have known untreated central nervous system disease

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (La Jolla).
  • Study treatment is given weekly by intravenous infusion (IV).
  • Search for NCT03573544 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org